Safety and efficacy of multipotent adult progenitor cells in acute ischaemic stroke (MASTERS): a randomised, double-blind, placebo-controlled, phase 2 trial

医学 安慰剂 祖细胞 冲程(发动机) 内科学 骨髓 外科 干细胞 病理 遗传学 机械工程 生物 工程类 替代医学
作者
David C. Hess,Lawrence R. Wechsler,Wayne M. Clark,Sean I. Savitz,Gary A. Ford,David Chiu,Dileep R Yavagal,Ken Uchino,David S. Liebeskind,Alexander P. Auchus,Souvik Sen,Cathy Sila,Jeffrey Vest,Robert Mays
出处
期刊:Lancet Neurology [Elsevier BV]
卷期号:16 (5): 360-368 被引量:319
标识
DOI:10.1016/s1474-4422(17)30046-7
摘要

Background Multipotent adult progenitor cells are a bone marrow-derived, allogeneic, cell therapy product that modulates the immune system, and represents a promising therapy for acute stroke. We aimed to identify the highest, well-tolerated, and safest single dose of multipotent adult progenitor cells, and if they were efficacious as a treatment for stroke recovery. Methods We did a phase 2, randomised, double-blind, placebo-controlled, dose-escalation trial of intravenous multipotent adult progenitor cells in 33 centres in the UK and the USA. We used a computer-generated randomisation sequence and interactive voice and web response system to assign patients aged 18–83 years with moderately severe acute ischaemic stroke and a National Institutes of Health Stroke Scale (NIHSS) score of 8–20 to treatment with intravenous multipotent adult progenitor cells (400 million or 1200 million cells) or placebo between 24 h and 48 h after symptom onset. Patients were ineligible if there was a change in NIHSS of four or more points during at least a 6 h period between screening and randomisation, had brainstem or lacunar infarct, a substantial comorbid disease, an inability to undergo an MRI scan, or had a history of splenectomy. In group 1, patients were enrolled and randomly assigned in a 3:1 ratio to receive 400 million cells or placebo and assessed for safety through 7 days. In group 2, patients were randomly assigned in a 3:1 ratio to receive 1200 million cells or placebo and assessed for safety through the first 7 days. In group 3, patients were enrolled, randomly assigned, and stratified by baseline NIHSS score to receive 1200 million cells or placebo in a 1:1 ratio within 24–48 h. Patients, investigators, and clinicians were masked to treatment assignment. The primary safety outcome was dose-limiting toxicity effects. The primary efficacy endpoint was global stroke recovery, which combines dichotomised results from the modified Rankin scale, change in NIHSS score from baseline, and Barthel index at day 90. Analysis was by intention to treat (ITT) including all patients in groups 2 and 3 who received the investigational agent or placebo. This study is registered with ClinicalTrials.gov, number NCT01436487. Findings The study was done between Oct 24, 2011, and Dec 7, 2015. After safety assessments in eight patients in group 1, 129 patients were randomly assigned (67 to receive multipotent adult progenitor cells and 62 to receive placebo) in groups 2 and 3 (1200 million cells). The ITT populations consisted of 65 patients who received multipotent adult progenitor cells and 61 patients who received placebo. There were no dose-limiting toxicity events in either group. There were no infusional or allergic reactions and no difference in treatment-emergent adverse events between the groups (64 [99%] of 65 patients in the multipotent adult progenitor cell group vs 59 [97%] of 61 in the placebo group). There was no difference between the multipotent adult progenitor cell group and placebo groups in global stroke recovery at day 90 (odds ratio 1·08 [95% CI 0·55–2·09], p=0·83). Interpretation Administration of multipotent adult progenitor cells was safe and well tolerated in patients with acute ischaemic stroke. Although no significant improvement was observed at 90 days in neurological outcomes with multipotent adult progenitor cells treatment, further clinical trials evaluating the efficacy of the intervention in an earlier time window after stroke (<36 h) are planned. Funding Athersys Inc.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Zzz发布了新的文献求助10
刚刚
华仔应助呸呸晓鹏采纳,获得10
1秒前
sunshine发布了新的文献求助10
2秒前
4秒前
5秒前
5秒前
小蘑菇应助钱宇成采纳,获得10
6秒前
wldsd发布了新的文献求助30
9秒前
充电宝应助王羊补牢采纳,获得10
12秒前
科研通AI2S应助酷酷飞烟采纳,获得10
12秒前
meng发布了新的文献求助30
13秒前
13秒前
完美小蘑菇完成签到,获得积分10
13秒前
兰是一个信仰完成签到,获得积分10
13秒前
潇湘雪月发布了新的文献求助10
16秒前
YJ888发布了新的文献求助10
16秒前
azusa完成签到,获得积分10
20秒前
昔年若许完成签到,获得积分10
27秒前
30秒前
31秒前
33秒前
高手发布了新的文献求助10
33秒前
善学以致用应助1WSQARFGRDSX采纳,获得10
34秒前
ZZZ完成签到,获得积分10
35秒前
ZZZ发布了新的文献求助10
37秒前
一一完成签到 ,获得积分10
37秒前
hp发布了新的文献求助10
39秒前
40秒前
姚世娇完成签到 ,获得积分10
42秒前
FashionBoy应助高手采纳,获得10
43秒前
meng完成签到,获得积分10
44秒前
chennn完成签到,获得积分10
44秒前
46秒前
47秒前
晗月完成签到,获得积分10
47秒前
情怀应助如意枫叶采纳,获得10
48秒前
量子星尘发布了新的文献求助10
50秒前
Akim应助SS采纳,获得10
51秒前
张雷应助清新的夜蕾采纳,获得20
51秒前
chennn发布了新的文献求助10
51秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
‘Unruly’ Children: Historical Fieldnotes and Learning Morality in a Taiwan Village (New Departures in Anthropology) 400
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3989242
求助须知:如何正确求助?哪些是违规求助? 3531393
关于积分的说明 11253753
捐赠科研通 3270010
什么是DOI,文献DOI怎么找? 1804868
邀请新用户注册赠送积分活动 882084
科研通“疑难数据库(出版商)”最低求助积分说明 809136